Ethics and Compliance – Connecticut
Statutory Price Disclosure for Connecticut Prescribers
Notice to Connecticut Prescribers
This information is being provided pursuant to Connecticut HB 6669. The prices listed below are wholesale acquisition cost (WAC) prices, which represent Innoviva Specialty Therapeutics, Inc.’s published list prices for the products sold to wholesalers and/or direct purchasers, before any discount, rebate, or other price reduction. These WAC prices are based on data obtained by Redbook, current as of 2/1/26.
The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made. Please refer to each product’s FDA-approved label and indication for further information.
Marketed Products:
GIAPREZA® (angiotensin II)
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use
ZEVTERA (ceftobiprole medocaril sodium for injection)
XERAVA® (eravacycline) for injection
Information for Connecticut Prescribers of Prescription Drugs
GIAPREZA® (angiotensin II)
Pursuant to Connecticut HB 6669, Innoviva Specialty Therapeutics, Inc. is providing Connecticut prescribers information about the wholesale acquisition cost (WAC) of this drug as well as information on the variation efficacy of the drug for different racial or ethnic groups, if available.
The WAC prices listed in the table below represent Innoviva Specialty Therapeutics, Inc.’s published list prices for the products sold to wholesalers and/or direct purchasers, before any discount, rebate, or other price reduction. These list prices are based on data obtained by Redbook, current as of 2/1/26.
The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.
| NDC | Product Description | Package Size | Package WAC |
| 68547-0501-02 | GIAPREZA® (angiotensin II) | 2.5MG for injection, available in a carton as a single dose vial | $1,899.00 |
| 68547-005-01 | GIAPREZA® (angiotensin II) | 0.5MG for injection, available in a carton as a single dose vial | $525.00 |
Connecticut law also requires manufacturers to provide information on the variation efficacy of the drug marketed to different racial and ethnic groups if such information is available. This information is not currently available for the product(s) listed above.
Information for Connecticut Prescribers of Prescription Drugs
XACDURO® (sulbactam for injection; durlobactam for injection)
Pursuant to Connecticut HB 6669, Innoviva Specialty Therapeutics, Inc. is providing Connecticut prescribers information about the wholesale acquisition cost (WAC) of this drug as well as information on the variation efficacy of the drug for different racial or ethnic groups, if available.
The WAC prices listed in the table below represent Innoviva Specialty Therapeutics, Inc.’s published list prices for the products sold to wholesalers and/or direct purchasers, before any discount, rebate, or other price reduction. These list prices are based on data obtained by Redbook, current as of 2/1/26.
The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.
| NDC | Product Description | Package Size | Package WAC |
| 68547-0111-10 | XACDURO® (sulbactam for injection; durlobactam for injection) | 0.5g-0.5g-1g co-packaged for intravenous use | $525.00 |
Connecticut law also requires manufacturers to provide information on the variation efficacy of the drug marketed to different racial and ethnic groups if such information is available. This information is not currently available for the product(s) listed above.
Information for Connecticut Prescribers of Prescription Drugs
ZEVTERA (ceftobiprole medocaril sodium)
Pursuant to Connecticut HB 6669, Innoviva Specialty Therapeutics, Inc. is providing Connecticut prescribers information about the wholesale acquisition cost (WAC) of this drug as well as information on the variation efficacy of the drug for different racial or ethnic groups, if available.
The WAC prices listed in the table below represent Innoviva Specialty Therapeutics, Inc.’s published list prices for the products sold to wholesalers and/or direct purchasers, before any discount, rebate, or other price reduction. These list prices are based on data obtained by Redbook, current as of 2/1/26.
The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.
| NDC | Product Description | Package Size | Package WAC |
| 68547-0578-10 | ZEVTERA (ceftobiprole medocaril sodium) | Single Dose Vial contains 667 mg, available in a carton of 10 single dose vials | $2,350.00 |
Connecticut law also requires manufacturers to provide information on the variation efficacy of the drug marketed to different racial and ethnic groups if such information is available. This information is not currently available for the product(s) listed above.
Information for Connecticut Prescribers of Prescription Drugs
XERAVA® (eravacyline)
Pursuant to Connecticut HB 6669, Innoviva Specialty Therapeutics, Inc. is providing Connecticut prescribers information about the wholesale acquisition cost (WAC) of this drug as well as information on the variation efficacy of the drug for different racial or ethnic groups, if available.
The WAC prices listed in the table below represent Innoviva Specialty Therapeutics, Inc.’s published list prices for the products sold to wholesalers and/or direct purchasers, before any discount, rebate, or other price reduction. These list prices are based on data obtained by Redbook, current as of 2/1/26.
The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.
| NDC | Product Description | Package Size | Package WAC |
| 71773-050-12 | XERAVA® (eravacyline) | 50 mg vial, available in a 12-vial carton | $875.00 |
| 71773-100-12 | XERAVA® (eravacyline) | 100 mg vial, available in a 12-vial carton | $1,499.00 |
Connecticut law also requires manufacturers to provide information on the variation efficacy of the drug marketed to different racial and ethnic groups if such information is available. This information is not currently available for the product(s) listed above.